Kornimate/medical-research-clean huggingface dataset:
interest of functional mri (magnetic resonance imagery) (in patients suffering from hepatocellular carcinoma and treated with yttrium

Conditions: Hepatocellular Carcinoma

Summary: for patients who are suffering from hepatocellular carcinoma and are treated with radioembolization, the purpose of this study is to analyse parameters of functional mris that are modified early and to detect parameters that vary significantly after treatment.


Eligibility criteria:
inclusion criteria: * early, intermediate, advanced, non metastatic hepatocellular carcinoma. indication for radioembolization validated after pluridisciplinary committee meeting. * isolated target on initial imagery (invasive hepatocellular carcinoma excluded) * who (world health organization) performance status: 0, 1 or 2 * if cirrhosis, child a score with total bilirubin less than 30 micromoles per liter * creatinine clearance more or equal to 30 ml/min * patient informed and consent signature obtained exclusion criteria: * invasive hepatocellular carcinoma without any isolated tumor * disease needing 2 injections of therasphere * thrombosis extending into the porta(thrombosis of one of left or right branch authorized), extra hepatic metastasis * previous treatment by chemoembolization, radiofrequency less than 3 months before radioembolization * no antiangiogenic concomitant treatment, 15 days before and 15 days after radioembolization, including sorafenib * associated disease which could prevent patient from receiving treatment * rmi contre-indication(particle or metal prosthesis, pacemaker, claustrophobia) or contrast product contre-indication (allergy) * patient already participating in an other therapeutic trial with an experimental drug * pregnant or childbearing potential women or breastfeeding women * minors, persons deprived of liberty or protected adults (maintenance of justice, guardianship or supervision) unable to comply with trial medical follow-up for geographical, social or psychological reasons * unable to sign an informed consent
is there a relationship between the ability of the trunk and lower extremities and walking function after stroke?

Conditions: Stroke

Summary: stroke leads to impairments at different levels. not only walking abilities are impaired after stroke but also trunk function, strength, balance and functional performance. even in the latter phase after stroke, both walking abilities and trunk function remain restricted. restoring walking function is often the main goal of rehabilitation after stroke and the focus of post-stroke physiotherapy is often on regaining walking and mobility. reduced walking ability after stroke is a predictor for discharge to a nursing home and associated with an increased probability of death. in addition, walking endurance, measured by a six-minute walking test, has a high correlation with community reintegration after a stroke. both trunk function and the ability to walk are often limited after stroke. a previous study observed that a significant correlation exists between these two functions, when measured with standardized clinical measurement scales . due to the functional relevance and the link between both functions, further investigation however is warranted. current lack of knowledge exists in investigating the relation between trunk and gait muscle strength, and this is key for informing clinical practice. for instance, should trunk muscle strength be a significant determinant of gait function, therapy should incorporate specific training for improving trunk muscle strength. the primary objective of the study is to investigate if trunk muscle function in combination with lower limb muscle function are significant determinants of walking ability after stroke. secondly, the investigators will examine if there are other determinants such as cognition, balance, spasticity, ability of performing selective movements and sensitivity of the lower extremities for walking ability.


Eligibility criteria:
inclusion criteria: 1. first stroke event. 2. residence in a rehabilitation ward. 3. two weeks until six months after a stroke event. 4. older than 18 years. 5. with no comorbidities other than stroke affecting trunk function or walking ability. comorbidities could be musculoskeletal problems or other neurological diseases. 6. with sufficient cognitive and language capacity to perform the assessment. exclusion criteria: 1. not able to give informed consent. 2. not approved informed consent. 3. subject does not understand the study procedures. 4. subject has any history of a major neurological disorder.

Keywords: stroke trunk lower extremities gait
treatment of patients with age-related macular degeneration with anecortave acetate

Conditions: Macular Degeneration

Summary: the purpose of this study is to evaluate whether anecortave acetate can slow or stop the progression of age-related macular degeneration in patients who do not qualify for other studies and have no other treatment options.

choroidal neovascularization (cnv), a complication of age-related macular degeneration (amd), is the most common cause of profound visual loss in the united states. laser photocoagulation has been shown to retard visual loss, however only about 20% of patients with cnv are eligible for laser treatment. conventional laser photocoagulation of cnv requires laser intensities adequate to coagulate proteins in the target tissue. due to the proximity of cnv to the center of vision (fovea), the intensity of laser irradiation necessary, and the heat conduction in the ocular tissues, collateral tissue damage often results which further compromises vision. recently, a new class of compounds (angiostatic steroids) have been found to inhibit the formation of new blood vessels (i.e. neovascularization) in the eye. one new angiostatic steroid, anecortave acetate (al-3789), may represent a breakthrough in the therapy of ocular neovascular diseases such as amd and diabetic retinopathy. anecortave acetate suppresses the formation of new blood vessels in a variety of models of neovascularization. unlike some of the angiostatic steroids, anecortave acetate appears to be lacking in the pharmacological activities typical of the steroid family (i.e. glucocorticoid, anti-inflammatory, cardiovascular, neurologic, diuretic, etc.) additionally, anecortave acetate has been shown to arrest lipopolysaccharide (lps) and basic fibroblast growth factors (bfgh) induced corneal neovascularization, to attenuate oxygen-induced retinopathy and to inhibit the growth of a highly vascularized intraocular tumor. the purpose of this study is to treat a small number of patients who would not normally qualify for the other anecortave acetate studies. these patients who are not eligible for the other anecortave acetate studies have no other treatment options and will likely experience a poor visual outcome as a result of their amd. these patients are excluded from other studies because of "occult" neovascularization and visual acuity worse than 20/40. sub-tenon's injection of either 15 mg or 30 mg of anecortave acetate will be administered at the university of iowa. the patients will be followed for a minimum of 24 months.

Eligibility criteria:
inclusion criteria: * choroidal neovascularization, mostly occult * visual acuity \> 20/40 in study eye exclusion criteria: * allergy to fluorescein dye * inability to stop warfarin prior to treatment * pregnancy * other serious ocular diseases or conditions

Keywords: age related macular degeneration
characterization & comparison of drugable mutations in primary and metastatic tumors, ctcs and cfdna in mbcpatients

Conditions: Metastatic Breast Cancer

Summary: characterization of the driver mutations in an individual metastatic breast cancer patient is critical for many reasons. effective targeted therapies require identifying genomic alterations in the tumoral tissue. the scarce efficacy of many currently available targeted drugs may be due to the outbreak of resistant clones with different genotype that already present at the initiation of therapy. it is well known the intra-tumor heterogeneity with genetic and non-genetic factors considered as the origin of the tumor cell-clon composition. the acquisition of multiple mutations (driver and passenger), altogether with the stage of differentiation, according to the cancer stem cell hypothesis, confers to the tumor cells clinically important properties, such as resistance to therapies and seeding abilities. moreover, there is a current challenge in establishing whether the metastatic cells arise from the most aggressive and dominant clone in the primary tumor or the metastasic tissue diverges with substantial genetic changes very early in the evolution of the disease. primary and metastatic tumor may have a close clonal relationship or evolve in parallel and acquire different genomic alterations. in the real life, it is plausible that both models coexist with different predominance according to the tumoral tissue and etiology. the study hypothesizes that breast cancer metastases and primary tumors could harbor different genomic profiles related to genomic regions of interest in a clinically relevant proportion of metastatic breast cancer patients. moreover, the genomic aberrations found in the metastatic breast cancer tissue could also be detected in ctcs and circulating free dna. if true, ctcs and circulating free dna would be convenient, non-invasive, easily accessible sources of genomic material for the analysis of mutations and other genomic aberrations.


Eligibility criteria:
inclusion criteria: * metastatic breast cancer confirmed by radiologic findings * ≥ 18 years old * able to give signed consent * availability to get the paraffin block of her primary tumor. * first metastatic relapse or tumor regrowth while on treatment for metastatic disease (progressive disease while on treatment) * biopsy of the metastatic site clinically indicated exclusion criteria: * inability to get a core sample from a metastatic site * bone disease only (the decalcification process usually prevents an appropriate genomic study). * unable to drawn peripheral blood * unable to give the informed consent * coagulation disorders * ecog status 3-4

Keywords: metastatic breast cancer ctcs cfdna genomics somatic mutations
effect of adjunctive metformin on recurrence of non-dm colorectal cancer stage ii high-risk/ iii colorectal cancer

Conditions: Non-DM Stage II High-risk Colorectal Cancer; Non-DM Stage III Colorectal Cancer

Summary: the aim of this study is to identify the effect of adjunctive metformin on recurrence of non-dm stage ii high-risk/ iii colorectal cancer. this study is open-label randomized controlled study. the primary endpoint is to compare the 3-year disease free survival between metformin group and non-metformin group. the secondary endpoint is to compare the 5-year overall survival and disease specific survival between two group, to identify the safety of metformin, and to compare the recurrence rate of polyps after polypectomy between two groups.


Eligibility criteria:
inclusion criteria: 1. patients with stage ii high-risk/ iii colorectal cancer who were taken an operation for cure, or patients with stage iii rectal cancer who were taken an chemoradiation therapy and subsequently operation 2. age 20 - 80 years 3. patients without dm 4. patients who have well performance status for chemotherapy 5. patients who are agreed the study protocol exclusion criteria: 1. patients with dm 2. patients who were diagnosed other cancers (≥ stage ii) within 5 years 3. patients who have familial adenomatous polyposis, hereditary non-polyposis colorectal cancer, or inflammatory bowel disease 4. patients who are taken other chemoprevention drugs (ex. nsaids, aspirin) 5. patients who have risk factors to increase lactic acidosis which are renal disease, lung disease, liver disease, or infectious disease 6. creatinine ≥ 1.5mg/dl (for male), ≥ 1.4mg/dl (for female) 7. patients with congestive heart failure which is needed to treat 8. patients who have allergic history of metformin 9. pregnancy
the effect of wrist ankle acupuncture on post-total hip arthroplasty pain

Conditions: Pain, Postoperative; Hip Osteoarthritis; Hip Fractures; Hip Injuries

Summary: total hip arthroplasty is one of the most cost-effective orthopedic surgical procedures which can restore hip function and improve the patient's quality of life. however, total hip arthroplasty is significantly associated with postoperative pain. pain after total hip arthroplasty surgery can adversely affect the patient's early postoperative recovery, postoperative mobility, and hinder rehabilitation. wrist ankle acupuncture (waa) is a simpler acupuncture technique, using fewer points, shallow needle insertion and lighter stimulation. wrist-ankle acupuncture as multimodal analgesia after orthopedic surgery is useful for reducing pain and reduce the incidence of post-surgical side effects. the primary aim of this study is to investigate whether wrist ankle acupuncture therapy gives better and results for post total hip arthroplasty pain than sham wrist ankle acupuncture

this is a clinical trial study to evaluate and compare the effects of wrist ankle acupuncture and sham wrist ankle acupuncture as a therapy for post total hip arthroplasty pain. the subjects are 32 males/female who just undergone total hip arthroplasty surgery and has returned to inpatient ward. they will be randomly assigned to 2 groups: (1) wrist ankle acupuncture and (2) sham wrist ankle acupuncture. the subjects will receive two sessions of treatment. the outcome will be assessed before treatment (baseline), after fist acupuncture session, after second acupuncture session and a day after the second session. patients and the outcome assessors will be blinded to the group allocation.

Eligibility criteria:
inclusion criteria: 1. patients undergoing elective primary total hip arthroplasty surgery at dr. cipto mangunkusumo hospital, persahabatan hospital, andfatmawati hospital 2. aged over 18 years 3. willing to sign informed consent exclusion criteria: 1. have a history of malignancy 2. revision total hip arthroplasty patient 3. post-total hip surgery patient treated in icu. 4. the patient has a mental disorder so he cannot understand the explanation given
evaluation of the quantiferon-tb test.

Conditions: Tuberculosis

Summary: to compare the results of the investigational test to the currently approved quantiferon-tb gold in-tube test.

to compare the specificity of the cst001 assay to the qft gold test in low tb exposure risk subjects and non-tuberculosis mycobacterial infections.

Eligibility criteria:
low-exposure risk group inclusion criteria: * no identified risk factors for tb infection exclusion criteria: * age less than 18 years or greater than 80 years * identified risk factors for tb infection non-tuberculous mycobacterial infection group inclusion criteria: * history of nontuberculous mycobacterial disease (pulmonary or extrapulmonary) in accordance with the 2007 ats/idsa criteria exclusion criteria: * age less than 18 years or greater than 80 years * identified risk factors for tb infection

Keywords: tuberculosis tb
seminal levels of pgk2 and acrv1 as predictors of micro-tese results in noa

Conditions: Male Infertility Due to Azoospermia

Summary: * measurement of pgk2 and acrv1 levels in the semen of infertile males undergoing testicular sperm extraction (tese). * correlate seminal levels of pgk2 and acrv1 with sperm retrieval results and histopathology analysis of testicular biopsy samples.


Eligibility criteria:
inclusion criteria: * infertile males with normal volume, functional (non-obstructive) azoospermia. * age: 18-45 years exclusion criteria: * patients with proven obstructive azoospermia. * cryptorchidism. * testicular agenesis and testicular atrophy. * patient with exposure to gonadal toxins like chemotherapy, radiotherapy, and alkylating agents.
the effect of positional device on the obstructive sleep apnea in patients with ischemic stroke

Conditions: Sleep Apnea, Obstructive; Brain Ischemia

Summary: supine positioning was reported to increase upper airway collapsibility, apnea frequency and duration. positional therapy, designed to minimize supine sleep, was reported to be beneficial in the general sleep apnea population. as supine sleep is very common in stroke patients, positional therapy might also have therapeutic effects. given differences between stroke patients with sleep apnea and the general sleep apnea patient, such as rolling ability, body mass index and daytime sleepiness, positional therapy results in the general population may not be applicable to the stroke patient. the effects of positional therapy in ischemic stroke patients with osa have not been well-investigated. we therefore performed a pilot randomized, controlled, cross-over study to test the following hypotheses: (1) positional therapy reduces the amount of nocturnal supine positioning in patients with subacute ischemic stroke, and (2) severity of sleep apnea improves, as reflected by apnea-hypopnea index (ahi), during positional therapy. the tolerability of positional therapy over a 3-month period in patients with ischemic stroke was also evaluated.

phase 1: in the first phase, a randomized, controlled, two-period cross-over study design (ab/ba) was used with no washout period. after an acclimatization period (3 days), during which the compliance of the positional device was monitored, each patient was randomized into either group i (sequence ab) or group ii (sequence ba). after commencement of treatment, the outcome measures were repeated on the last day of each treatment period. on the control night (b), subjects used the lumbar corset and were positioned ad lib. phase 2: in the second phase of the study which began immediately after attainment of the first phase, subjects were randomized on a 1:1 basis, in a parallel group design, to 3 months of positional devices or sleeping ad lib. at 3 months later all subjects were interviewed face to face to determine the barthel index and the patient health questionnaire 9-item depression scale. subjects in the positional devices group were also evaluated about devices adherence using the following questions: use of the device all nights, most nights, some nights, or no nights.

Eligibility criteria:
inclusion criteria: * patients with ischemic stroke (\> 1month, within 12 months) and moderate-to-severe osa (ahi\>15) who could wear the positional devices not interfering with his/her sleep. exclusion criteria: * unclear consciousness * unstable vital sign or neurologic sign * unstable medical conditions

Keywords: supine position
validation of a new generation of orthopedic brace for treating adolescent idiopathic scoliosis by using growth modulation

Conditions: Scoliosis; Adolescent Idiopathic Scoliosis

Summary: adolescent idiopathic scoliosis affects 3-4% of the canadian population, of which about 10% will need a brace treatment during pubertal growth spurt. our team has developed an innovative conception method for brace design by simulating the growth modulation using numerical models. those models are customized to each patient. in this project, the investigators will evaluate the effectiveness of this platform customized treatment and validate its clinical application.


Eligibility criteria:
inclusion criteria: * ais diagnosis * risser 0-2 * primary curve angles 20 degrees - 40 degrees * if female, either premenarchal or less than 18 months postmenarchal. exclusion criteria: * patients with a pre-existing cardiovascular condition * patients with a symptom of a neurological disorder * patients with any other disorder of the musculoskeletal system affecting the lower limbs

Keywords: scoliosis spine deformity brace growth modulation
study to evaluate the safety and efficacy of cntx-4975 in subjects with chronic, moderate to severe osteoarthritis knee pain

Conditions: Osteoarthritis

Summary: the purpose of this study is to evaluate the safety and efficacy of a single injection of cntx-4975 in subjects with chronic, moderate to severe osteoarthritis knee pain.


Eligibility criteria:
inclusion criteria: * radiography of both knees with a posterior-anterior, fixed flexion view taken during the screening period. the index knee must show evidence of chronic oa. * moderate to severe pain in the index knee associated with oa must be stable for a minimum of 2 months prior to screening, as assessed by the investigator. * a specified mean pain score in the index knee over the 7 days prior to dosing, based on question a1 of the western ontario and mcmaster universities osteoarthritis index (womac a1). * specified baseline and screening scores on the womac a1 * body mass index ≤ 45 kg/m2. * subjects must have had a therapeutic failure (no relief, or inadequate relief), and/or aes resulting in stopping treatment, and/or contraindication to the standard of care appropriate to the severity of the index knee oa pain they are experiencing. exclusion criteria: * joint replacement surgery of the index knee at any time, or open surgery of the index knee in the past 12 months. * prior arthroscopic surgery of the index knee within 3 months of screening. * any painful conditions of the index knee due to joint disease other than oa. * mild pain in the non-index knee when walking. * other chronic pain anywhere in the body that requires the use of analgesic medications. * secondary oa of the index knee due to acute traumatic injury. * significant current or past instability (e.g., cruciate ligament tear or rupture or previous repair) or misalignment (\> 10 degrees varus or valgus) of the index knee * has used topical capsaicin on the index knee within 90 days of screening. * corticosteroid injection in the index knee within 90 days of screening. * received ia viscosupplementation (e.g., synvisc®, hyalgan®) within 90 days of screening. * prior participation in an algrx 4975 or cntx-4975 study. * has any of the following characteristics: 1. active or historic substance use disorder within the previous year as defined by the diagnostic and statistical manual for mental health disorders, fifth edition, or 2. tests positive upon urine drug screen for a substance of abuse. * has moderate to severe depression or anxiety.
mindfulness training hidradenitis suppurativa (hs)

Conditions: Hidradenitis Suppurativa; Quality of Life

Summary: the purpose of this research is to investigate the effectiveness of mindfulness training on the quality of life of hidradenitis suppurativa (hs) patients. hs can have a profound impact on quality of life.


Eligibility criteria:
inclusion criteria: * hidradenitis suppurativa patients registered in the university of miami hospital dermatology system. patients can have lesions present at the time of study participation exclusion criteria: * individuals with any of the following: active drug addictions, untreated post traumatic stress disorder (ptsd), psychosis or suicidal ideations * adults unable to consent * pregnant women * prisoners * individuals below the age of 18 years old * individuals who do not speak english